Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Neil Formica"'
Autor:
Neil Formica, Raburn Mallory, Gary Albert, Michelle Robinson, Joyce S Plested, Iksung Cho, Andreana Robertson, Filip Dubovsky, Gregory M Glenn, nCoV-101 Study Group
Publikováno v:
PLoS Medicine, Vol 18, Iss 10, p e1003769 (2021)
BackgroundNVX-CoV2373 is a recombinant severe acute respiratory coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant.Methods and findingsThe phase 2 component of our r
Externí odkaz:
https://doaj.org/article/d8f07241dfa4407b835b334d15d8c76c
Autor:
Raburn M Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Holly L Hammond, Lauren Baracco, James Logue, Matthew B Frieman, Gale Smith, Nita Patel, Gregory M Glenn, Mark Adams, Mark Arya, Eugene Athan, Ira Berger, Paul Bradley, Toby Briskin, Richard Glover II, Paul Griffin, Joshua Kim, Scott Kitchener, Terry Klein, Amber Leah, Indika Leelasena, Charlotte Lemech, Jason Lickliter, Mary Beth Manning, Fiona Napier-Flood, Paul Nugent, Susan Thackwray, Mark Turner
Publikováno v:
The Lancet. Infectious diseases. 22(11)
Emerging SARS-CoV-2 variants and evidence of waning vaccine efficacy present substantial obstacles towards controlling the COVID-19 pandemic. Booster doses of SARS-CoV-2 vaccines might address these concerns by amplifying and broadening the immune re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b9de8292fa80c9a4a06d0e79ac14652
https://pubmed.ncbi.nlm.nih.gov/35963271
https://pubmed.ncbi.nlm.nih.gov/35963271
Autor:
Andreana Robertson, Gary Albert, Neil Formica, Michelle Robinson, Iksung Cho, Joyce S. Plested, Filip Dubovsky, Gregory M. Glenn, Raburn Mallory
BackgroundNVX-CoV2373 is a recombinant severe acute respiratory coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant.MethodsThe phase 2 component of our randomized, pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a5e79efd32900f6574dc2ffed705eca
https://doi.org/10.1101/2021.02.26.21252482
https://doi.org/10.1101/2021.02.26.21252482
Autor:
Gale Smith, Vivek Shinde, Shane Cloney-Clark, Bethanie E. Wilkinson, Cheryl Keech, Pedro A. Piedra, Mingzhu Zhu, Joyce S Plested, Haixia Zhou, Louis Fries, Matthew B. Frieman, Neil Formica, Andreana Robertson, Paul M. Griffin, Jason D. Lickliter, Marisa McGrath, James Logue, Gary Albert, Nita Patel, Maggie Lewis, Stuart Weston, Patricia Price-Abbott, Susan Neal, Gregory M. Glenn, Iksung Cho, Robert Haupt, Patricia Reed, Chinar Desai, Kathleen Callahan
Publikováno v:
New England Journal of Medicine
The New England Journal of Medicine
The New England Journal of Medicine
Background NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant. Methods We initiated a randomized, plac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88141ab864c98bfefbf552a491188c07
https://pubmed.ncbi.nlm.nih.gov/32877576
https://pubmed.ncbi.nlm.nih.gov/32877576
Autor:
Patricia Price-Abbott, Robert Haupt, Nita Patel, Marisa McGrath, Cheryl Keech, Paul M. Griffin, Gale Smith, Vivek Shinde, Jason D. Linkliter, Chinar Desai, Maggie Lewis, Neil Formica, Pedro A. Piedra, Haixia Zhou, Kathleen Callahan, Gregory M. Glenn, Iksung Cho, Stuart Weston, Susan Neal, Shane Cloney-Clark, Joyce S. Plested, Patricia Reed, Matthew B. Frieman, Gary Albert, Mingzhu Zhu, Andreana Robertson, James Logue, Louis Fries, Bethanie Wilkinson
BackgroundNVX-CoV2373 is a recombinant nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins. We present the Day 35 primary analysis of our trial of NVX-CoV2373 with or without the saponin-based Matrix-M1 adjuvant in he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::753257e551a27c18fa29c2150d5a4dcc
https://doi.org/10.1101/2020.08.05.20168435
https://doi.org/10.1101/2020.08.05.20168435
Autor:
John T. Treanor, Neil Formica, Vince Matassa, Frank R. Albano, Jane Leong, Daphne C. Sawlwin, Alison L Jones, Jolanta Airey
Publikováno v:
Vaccine. 35:1856-1864
Background Vaccination is the most effective means of influenza prevention. Efficacy of trivalent vaccines may be enhanced by including both B strain lineages. This phase 3, double-blind study assessed the immunogenicity and safety/tolerability of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49999864c1af54b80cf6b301998a35aa
https://doi.org/10.1016/j.vaccine.2017.02.066
https://doi.org/10.1016/j.vaccine.2017.02.066
Autor:
Frank R. Albano, Daphne C. Sawlwin, Vince Matassa, Jane Leong, Alison L Jones, Jolanta Airey, Neil Formica
Publikováno v:
Vaccine. 35(20)
Background Seqirus 2010 Southern Hemisphere split-virion trivalent inactivated influenza vaccine (IIV3) was associated with increased febrile reactions in children. Studies in vitro concluded that increasing concentrations of splitting agent decrease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7842be1f82f10aecec4014de84e67996
https://pubmed.ncbi.nlm.nih.gov/28390934
https://pubmed.ncbi.nlm.nih.gov/28390934
Autor:
Frank R. Albano, Daphne C. Sawlwin, Alison Graves-Jones, Jolanta Airey, Neil Formica, Jane Leong
Publikováno v:
Open Forum Infectious Diseases. 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4a44fba7bcb059d025ac46e643f4771
https://doi.org/10.1093/ofid/ofw172.624
https://doi.org/10.1093/ofid/ofw172.624
Autor:
Maryanne V. Skeljo, Gunter Hartel, Russell L. Basser, David Ryan, Terry Nolan, Georgina Pearce, Kelly Papanaoum, Peter Richmond, Maria Zambon, Jillian Bennet, Neil Formica, Katja Hoschler
Publikováno v:
Vaccine. 26:4160-4167
Objective The primary objective was to evaluate the safety and immunogenicity of a prototype inactivated, split-virus H5N1 (avian influenza A) vaccine. A secondary objective was to assess the cross-reactivity of immune responses to two variant clade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a14b92aa7b9c544abc1c0962a9b36871
https://doi.org/10.1016/j.vaccine.2008.05.077
https://doi.org/10.1016/j.vaccine.2008.05.077
Autor:
Emmanuel B. Walter, Rebecca C. Brady, Irene Graham, Maryanne V. Skeljo, Gunter Hartel, James D Campbell, Jillian Bennet, Cornelia L. Dekker, Kathryn M. Edwards, Thomas R. Cate, Dora Y. Ho, Neil Formica, H. Keipp Talbot, John J. Treanor, Wendy A. Keitel, Patricia L. Winokur
Publikováno v:
Vaccine. 26:4057-4061
To augment the available influenza vaccine supply, a phase III study was conducted to evaluate the immunogenicity, safety, and consistency of a new trivalent inactivated influenza vaccine manufactured by CSL Limited. Healthy adults (ages 18-64) were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fef7f66d22dd72e6e6b17cfede96a32
https://doi.org/10.1016/j.vaccine.2008.05.024
https://doi.org/10.1016/j.vaccine.2008.05.024